Quantitative retention-activity relationship models of angiotensin converting enzyme inhibitors using biopartitioning micellar chromatography

Journal of Chromatographic Science

Volumn 48, Issue 2, 2010, Pages 134-139

  Wang, Shu Rong ^a,b   Chen, Cong ^b   Xiong, Mei Jin ^b   Wu, Li Ping ^b   Ye, Li Ming ^b  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849131116     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.2.134     Document Type: Article

References (33)

1. A. R. Hilgers, R. A. Conradi, and P. S. Burton. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7: 902-910 (1990).
2. F. Beigi, Q. Yang, and P. Lundahl. Immobilized-liposome chromatographic analysis of drugpartitioningintolipidbilayers. J. Chromatogr. A 704: 315-321(1995).
3. A. Detroyer, Y. Vander Heyden, I. Cambre, and D. L. Massart. Chemometric comparison of recent chromatographic and electrophoretic methods in a quantitative structure-retention and retention-activity relationship context. J. Chromatogr. A 986: 227-238 (2003).
4. L. Escuder-Gilabert, S. Sagrado, R. M. Villanueva-Camanas, and M. J. Medina-Hernández. Development of predictive retention-activity relationship models of non-steroidal anti-inflammatory drugs by micellar liquid chromatography: comparison with immobilized artificial membrane columns. J. Chromatogr. B 740: 59-70 (2000).
5. C. Quiñones-Torrelo, Y. Martin-Biosca, J. J. Martínez-Pla, S. Sagrado, R. M. Villanueva-Camañas, and M. J. Medina-Hernández. QRAR models for central nervous system drugs using biopartitioning micellar chromatography. Mini. Rev. Med. Chem. 2: 145-161 (2002).
6. T. Ma, L. M. Ye, and Y. Chen. The application of quantitative retention-activity relationship models in prediction of oral drug absorption and biological activity. Asian J. Drug Metabolism Pharmacokinet. 4: 251-260 (2004).
7. L. M. Ye, T. Ma, C. Chen, and Y. Chen. Study on predictive quantitative retention-activity relationship models of non-steroidal anti-inflammatory drugs by micellar liquid chromatography. J. Chin. Pharm. 40: 1737-1740 (2005).
8. S. R. Wang, Y. Chen, L. P. Wu, W. J. Miao, M. J. Xiong, C. Chen, Z. R. Zhong, and L. M. Ye. Development of predictive quantitative retention-activity relationship models of HMG-CoA reductase inhibitors by biopartitioning micellar chromatography. J. Pharm. Biomed. Anal. 46: 243-249 (2008).
9. L. P. Wu, Y. Chen, S. R. Wang, C. Chen, and L. M. Ye. Quantitative retention-activity relationship models for quinolones using biopartitioning micellar chromatography. Biomed. Chromatogr. 22: 106-114 (2008).
10. C. Pidgeon, S. Ong, H. Liu, X. Qiu, M. Pidgeon, A. H. Dantzig, J. Munroe, W. J. Hornback, J. S. Kasher, L. Glunz, and T. Szczerba. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem. 38: 590-594 (1995).
11. K. Balon, B. U. Riebesehl, and B. W. Muller. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res. 16: 882-888 (1999).
12. M. Molero-Monfort, L. Escuder-Gilabert, R. M. Villanueva-Camanas, S. Sagrado, and M. J. Medina-Hernández. Biopartitioning micellar chromatography: an in vitro technique for predicting human drug absorption. J. Chromatogr. B 753: 225-236 (2001).
13. L. Escuder-Gilabert, J. J. Martínez-Pla, S. Sagrado, R. M. Villanueva-Camanas, and M. J. Medina-Hernández. Biopartitioning micellar separation methods: modelling drug absorption. J. Chromatogr. B 797: 21-35 (2003).
14. C. Quinones-Torrelo, S. Sagrado, R. M. Villanueva-Camanas, and M. J. Medina-Hernandez. Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography. J. Med. Chem. 42: 3154-3162 (1999).
15. th ed. M. J. O'Neil, A. Smith and P. E. Heckelman, Whitehouse Station, NJ, Merck, 2001, pp. 176-1561.
16. X. Z. Qin, D. P. Ip, and E. W. Tsai. Determination and rotamer separation of enalapril maleate by capillary electrophoresis. J. Chromatogr. 626: 251-258 (1992).
17. http://202.115.100.251:86/webspirs
18. K. L. Duchin, D. N. Mckinstry, and A. I. Xohen. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin. Pharmacokinet. 14: 241-259 (1988)
19. J. D. Irvin and J. M. Viau. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am. J. Med. 81(suppl 4C): 46-50 (1986).
20. K. R. Lees, S. T. Green, and J. L. Reid. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin. Pharmacol. Ther. 44: 418-425 (1988).
21. K. R. Lees and J. L. Reid. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin. Pharmacol. Ther. 41: 597-602 (1987).
22. G. Kaiser, R. Ackermann, and S. Brechbuhler. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharm. Drug Disp. 10: 365-376 (1989).
23. Kenta Yamanaka, Shigeki Morikawa, Kazuo Murata, Kiyoshi Banno, Tadashi Sato, Tsutomu Takai, Takchiko Suzuki, Masakazu Mizobe, Masao Ito, and Kaichiro Ishibashi. Radioimmunoassay for imidapril, a new angiotensin-converting enzyme inhibitor, and imidaprilat, its active metabolite, in human plasma and urine. J. Pharm. Biomed. Anal. 14: 281-287 (1996).
24. S. Noble and E. M. Sorkin. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs 49: 750-766 (1995).
25. J. C. Song. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. 41: 207-224 (2002).
26. C. Thuillez, C. Richer, and J. F. Giudicelli, Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers. Am. J. Cariol. 59: 38D-44D (1987).
27. S. Meisel, A. Shamiss, and T. Rosenthal. Clinical pharmacokinetics of ramipril. Clin. Pharmacokinet. 26: 7-15 (1994).
28. R. J. Francis, A. N. Brown, L. Kler, T. Fasanella d'Amore, J. Nussberger, B. Waeber, and H. R. Brunner. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J. Cardvasc. Pharmacol. 9: 32-38 (1987).
29. X. L. Zhang. The reference of drug clinical information, volume lst, sichuan science and technology, Chengdu, Sichuan, 2005, pp. 609-621.
30. A. Salvetti. Newer ACE inhibitors. A look at the future. Drugs 40: 800-828 (1990).
31. A. N. Wadworth and R. N. Brogen. Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 41: 378-399 (1991).
32. A. Marzo, L. Dal Bo, P. Mazzucchelli, N. C. Monti, R. A. Tettamanti, F. Crivelli, M. R. Uhr, S. Ismaili, and A. Giusti. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung 49: 992-996 (1999).
33. D. Murdoch and D. McTavish. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 43: 123-140 (1992).